Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 88Gynecologic 3Thoracic 2Sarcoma 2Head & Neck 2Genitourinary 2Breast 2

Conditions

Head and Neck Neoplasms 13Squamous Cell Carcinoma of Head and Neck 8Nasopharyngeal Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2Osteosarcoma 2Optic Nerve Glioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasm Metastasis 2Melanoma 2Familial ependymoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Astrocytoma 2Wilms Tumor 1Thyroid Neoplasms 1Testicular Neoplasms 1Teratoma 1Spinocerebellar Degenerations 1

Interventions

pembrolizumab 20Docetaxel 8Carboplatin 8Fluorouracil 6Cisplatin 6Nivolumab 5fludarabine 4Trastuzumab 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Cyclophosphamide 4Biopsy 4Bevacizumab 4fludarabine phosphate 3durvalumab 3atezolizumab 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Capecitabine 3Albumin-Bound Paclitaxel 3ulixertinib 2tisotumab vedotin 2spartalizumab 2belinostat 2adavosertib 2X-Rays 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Oxaliplatin × Head & Neck × Clear all
NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡